MENOPAUSE & FAMILY PLANNING

09:00-10:30
MANAGEMENT OF MENOPAUSAL SYMPTOMS 
 Capsule

Since the unfortunate universal drop in HT in 2002, we have come almost full circle in understanding the benefits of using HT in young, symptomatic healthy women at the onset of menopause.  However, the translation to prescriptions is still lagging. Where do we stand today?
 Chairpersons

Mark Brincat, Malta
Marco Gambacciani, Italy

09:00-09:45
09:00-09:15
09:15-09:30
09:30-09:45
 
Debate: HRT for menopausal women should rebound to pre-WHI era
Yes: Serge Rozenberg, Belgium
No: Sven O. Skouby, Denmark 
Discussion
 
09:45-10:30
09:45-10:00
10:00-10:15
10:15-10:30 

Debate: Are estrogens cancer protective on the breast?
Yes: Herjan J.T. Coelingh Bennink, The Netherlands
No: Serge Rozenberg, Belgium 
Discussion

10:50-12:20
GENITOURINARY SYNDROME OF MENOPAUSE (GSM)
 Capsule

NAMS and ISSWSH have published a new terminology for "volvovaginal atrophy" i.e. "genitourinary syndrome of menopause (GSM)."  GSM is a collection of symptoms and signs associated with a decrease in estrogen and other sex steroids involving changes to the labia, clitoris, vestibule, vagina, urethra and bladder. GSM may include genital symptoms of dryness, burning, and irritation; sexual symptoms of lack of lubrication, discomfort or pain, and impaired function; and urinary symptoms of urgency, dysuria and recurrent urinary tract infections." What are the treatment options?
 Chairpersons

Santiago Palacios, Spain
Christian Egarter, Austria 
10:50-11:10
Anatomical and physiological changes of the volvovaginal tract in the peri-menopause 
Alessandra Graziottin, Italy
11:10-11:35 Isoflavones and the gut microbiome
Herman Depypere, Belgium
11:35-11:45 Vaginal Erbium Laser the second generation thermotherapy for the genitourinary syndrome of menopause
Marco Gambacciani, Italy
11:45-12:10 Muscolo Skeletal changes in the Menopause and Hormone Therapy
Mark Brincat, Malta
12:30-14:00
NEW OPTIONS FOR HORMONAL TREATMENT
Chairpersons

Irene  Lambrinoudaki, Greece
Sven O. Skouby, Denmark
Alessandra Graziottin, Italy
 Capsule

The new candidate in the market which contains estrogens and bazedoxifene that is associated with a decrease in hot flushes, low rate of endometrial hyperplasia, low breast pain and density, increase in BMD, and no increase in VTE, would prescription bounce back to the pre-WHI era?
12:30-12:50
Mechanism of action of the estrogens/bazedoxifene
Christian Egarter, Austria  
12:50-13:15 Efficacy and safety of conjugated estrogens/bazedoxifene (CE/BZA)
Santiago Palacios, Spain
13:15-13:35 Positioning of estrogens/bazedoxifene in the treatment of menopausal women
Serge Rozenberg, Belgium
13:35-14:00 New treatments for OP
Santiago Palacios, Spain
14:50-16:20
MENSTRUAL DISORDER AND OFFICE GYNECOLOGY
Chairperson
Christian Egarter, Austria
Irene  Lambrinoudaki, Greece
Aleksander Radulovic, Serbia
14:50-15:10
Pathogenic biofilms: Leading contributors to recurrent vaginitis and cystitis
Alessandra Graziottin, Italy
15:10-15:35
Dydrogesterone treatment for menstrual cycle regularization in routine clinical practice in Russia, Ukraine, Kazakhstan and Uzbekistan: Results from a post-Marketing, observational study
Natalia Podzolkova,Russia
Tetiana Tatarchuk, Aikerm Doshchanova, Gulsara Eshimbetova
15:35-16:00 Treatment of pelvic organ prolapses using Erbium YAG laser thermo therapy-12 and 24 months follow-up
Sabina Sencar & Urska Bizjak-Ogrinc, Slovenia
16:00-16:20 Managing medical gynecology in a community setting
Paula Briggs, UK
16:40-18:10
OC's
Capsule

Thromboembolism is a threatening complication of OC’s. What are the differences between various preparations in the market?  Can we diagnose and prevent this severe complication?
Chairpersons

Alessandra Graziottin, Italy 
Christian Egarter, Austria
16:40-17:10
Mechanism of OC’s related thrombosis
Sven O. Skouby, Denmark
17:10-17:40 If contraception is free in the UK then why do we have such a high rate of unplanned pregancies?
Paula Briggs, UK
17:40-18:10 Contraception, menstrual symptoms and Hormone Free Interval: The shorter the better? 
Alessandra Graziottin, Italy
09:00-10:30
HT: ONLY TO SYMPTOMATIC WOMEN?
Organized by EMAS
Chairperson

Serge Rozenberg, Belgium
Irene  Lambrinoudaki, Greece
09:00-09:20
HT: For early menopause and only to symptomatic women?
Sven O. Skouby, Denmark
09:20-09:45 Is there a role for HT in prevention?
Rogerio Lobo, USA
09:45-10:05 Gynecological and sexual issues in young women with breast cancer
Alessandra Graziottin, Italy
10:05-10:30 Predicting diseases later in life
Serge Rozenberg, Belgium
10:50-12:20
 VULVAR PAIN SYNDROME
Chairperson

Jorma Paavonen, Finland
10:50-11:00

Introduction
Jorma Paavonen, Finland
11:00-11:15
11:15-11:30
Etiopathogenesis
Inflammatory aspects: Päivi Tommola, Finland
Genetic aspects: Ulrika Heddini, Sweden 
11:30-11:50
11:50-12:10
 Treatment
Conservative management: Gilbert Donders, Belgium
Surgical treatment, vestibulectomy: Jorma Paavonen, Finland
12:10-12:20 Panel discussion 
12:30-14:00
GYNE-ONCOLOGY I
Chairpersons
Pierluigi Benedetti Panici, Italy 
Laszlo Ungar, Hungary 
12:30-13:30

12:30-12:50
12:50-13:10
13:10-13:30

Debate: Upfront maximal debulking surgery versus neo-adjuvant chemotherapy for advanced ovarian cancer
Upfront debulking: Pierluigi Benedetti Panici, Italy
Neo-adjvant: Robert Koiss, Hungary
Discussion

13:30-14:00 Autologous stem cells for the treatment of Rokytanski syndrome
Pierluigi Benedetti Panici, Italy
14:50-16:20
GYNE-ONCOLOGY II 
Chairperson
Pierluigi Benedetti Panici, Italy
14:50-15:20 Perioperative management in patients treated with aggressive oncologic surgery
Laszlo Ungar, Hungary
15:20-16:20
15:20-15:40
15:40-16:00
16:00-16:20

Debate: Lymphadenectomy in endometrial cancer
Yes: Laszlo Ungar, Hungary
No: Pierluigi Benedetti Panici, Italy
Discussion